Acid ceramidase and human disease
- PMID: 17064658
- DOI: 10.1016/j.bbamem.2006.08.019
Acid ceramidase and human disease
Abstract
Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23; AC) is the lipid hydrolase responsible for the degradation of ceramide into sphingosine and free fatty acids within lysosomes. The enzymatic activity was first identified over four decades ago, and is deficient in the inherited lipid storage disorder, Farber Lipogranulomatosis (Farber disease). Importantly, AC not only hydrolyzes ceramide into sphingosine, but also can synthesize ceramide from sphingosine and free fatty acids in vitro and in situ. This "reverse" enzymatic activity occurs at a distinct pH from the hydrolysis ("forward") reaction (6.0 vs. 4.5, respectively), suggesting that the enzyme may have diverse functions within cells dependent on its subcellular location and the local pH. Most information concerning the role of AC in human disease stems from work on Farber disease. This lipid storage disease is caused by mutations in the gene encoding AC, leading to a profound reduction in enzymatic activity. Recent studies have also shown that AC activity is aberrantly expressed in several human cancers, and that the enzyme may be a useful cancer drug _target. For example, AC inhibitors have been used to slow the growth of cancer cells, alone or in combination with other established, anti-oncogenic treatments. Aberrant AC activity also has been described in Alzheimer's disease, and overexpression of AC may prevent insulin resistant (Type II) diabetes induced by free fatty acids. Current information concerning the biology of this enzyme and its role in human disease is reviewed within.
Similar articles
-
The molecular medicine of acid ceramidase.Biol Chem. 2015 Jun;396(6-7):759-65. doi: 10.1515/hsz-2014-0290. Biol Chem. 2015. PMID: 25938220 Review.
-
Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling.J Biol Chem. 2005 May 20;280(20):20148-53. doi: 10.1074/jbc.M412769200. Epub 2005 Mar 17. J Biol Chem. 2005. PMID: 15774472
-
The reverse activity of human acid ceramidase.J Biol Chem. 2003 Aug 8;278(32):29948-53. doi: 10.1074/jbc.M303310200. Epub 2003 May 22. J Biol Chem. 2003. PMID: 12764132
-
KLF6 is one transcription factor involved in regulating acid ceramidase gene expression.Biochim Biophys Acta. 2005 Dec 30;1732(1-3):82-7. doi: 10.1016/j.bbaexp.2006.01.002. Epub 2006 Jan 26. Biochim Biophys Acta. 2005. PMID: 16500425
-
The N-acylethanolamine-hydrolyzing acid amidase (NAAA).Chem Biodivers. 2007 Aug;4(8):1914-25. doi: 10.1002/cbdv.200790159. Chem Biodivers. 2007. PMID: 17712833 Review.
Cited by
-
Gene expression profiling in pachyonychia congenita skin.J Dermatol Sci. 2015 Mar;77(3):156-65. doi: 10.1016/j.jdermsci.2015.01.001. Epub 2015 Jan 14. J Dermatol Sci. 2015. PMID: 25656049 Free PMC article.
-
The role of sphingosine 1-phosphate and its receptors in cardiovascular diseases.J Cell Mol Med. 2020 Sep;24(18):10290-10301. doi: 10.1111/jcmm.15744. Epub 2020 Aug 17. J Cell Mol Med. 2020. PMID: 32803879 Free PMC article. Review.
-
Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.Adv Exp Med Biol. 2020;1274:101-135. doi: 10.1007/978-3-030-50621-6_6. Adv Exp Med Biol. 2020. PMID: 32894509 Review.
-
Sphingolipids and mitochondrial apoptosis.J Bioenerg Biomembr. 2016 Apr;48(2):153-68. doi: 10.1007/s10863-015-9602-3. J Bioenerg Biomembr. 2016. PMID: 25620271 Free PMC article. Review.
-
The role of ceranib-2 and its nanoform on the decrease of telomerase levels in human non-small cell cancer.Mol Biol Rep. 2024 Aug 6;51(1):889. doi: 10.1007/s11033-024-09838-2. Mol Biol Rep. 2024. PMID: 39105852
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical